Takeda Pharmaceutical Company Limited Announces Financial Results for the Fiscal Year Ended March 31, 2013 and Forecasts for the

  Takeda Pharmaceutical Company Limited Announces Financial Results for the
  Fiscal Year Ended March 31, 2013 and Forecasts for the Fiscal Year Ending
                                March 31, 2014

  PR Newswire

  OSAKA, Japan, May 9, 2013

OSAKA, Japan, May 9, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company
Limited ("Takeda", "the Company") announced today the consolidated financial
results for the fiscal year ended March 31, 2013, and forecasts of
consolidated results for the fiscal year ending March 31, 2014. The Company is
listed on the Tokyo Stock Exchange, First Section with the stock code "4502"
and prepares financial statements according to Japan GAAP.

                                                   Year-on-year   Forecasts
                                       Fiscal 2012
                          Fiscal 2011                 change    Fiscal 2013*
                         (billion yen)    yen)         (%)      (billion yen)
Net sales                      1,508.9     1,557.3         +3.2       1,590.0
Operating income                 265.0       122.5        -53.8         140.0
Operating income excl.
Special factors **               414.5       267.5        -35.5         280.0
Ordinary income                  270.3       113.2        -58.1         125.0
Net income                       124.2       131.2         +5.7          95.0
Net income excl.
Income/Loss & Special
factors ***                      248.2       184.6        -25.6         185.0
Earnings per share          157.29 yen  166.25 yen         +5.7    120.34 yen
EPS excl. Extraordinary
Income/Loss & Special
factors ***                 314.38 yen  233.78 yen        -25.6    234.34 yen
EBITDA excl.
Extraordinary income and
loss ****                        422.6       323.9        -23.4         340.0

Takeda achieved net sales growth in fiscal year 2012 (fiscal year ended March
31, 2013). This growth was supported by increases in emerging markets made
possible by the acquisition of Nycomed. In addition, Takeda achieved sales
gains for new products in Japan, the United States and Europe, including
Nesina (treatment for type 2 diabetes), Reminyl (for patients with
Alzheimer-type dementia), Azilva (for hypertension), Dexilant (for
gastroesophageal reflux disease), and Uloric (for hyperuricemia for patients
with chronic gout). These gains offset the decrease in sales caused by the
entry of the generic version of Actos.

In addition, Takeda has been proactively making strategic investments to
expand and strengthen its R&D pipeline, progressing a number of late-stage
compounds and filing new drug applications in the United States, Europe and
Japan. The Company has also continued the globalization of its operating model
and enhanced its business infrastructure in emerging markets for future

"In fiscal 2012 we chose to make critical investments to drive mid- and
long-range growth while simultaneously preparing for the launch of a new
Mid-Range Growth Strategy that focuses on the development of our global
business operations in developed and emerging countries, and the realization
of scientific and business process innovation. Our improved marketing
strategy, extensive late stage pipeline and overall efforts will make Takeda's
operating model robust and efficient as a world-class pharmaceutical company.
Based on these initiatives, Takeda is committed to the return to a solid
growth trajectory in both sales and profit as early as possible," said
Yasuchika Hasegawa, President & CEO, Takeda.

For further information on the financial results as well as the company's
Mid-Range Growth Strategy starting from the fiscal year 2013, please visit the
Takeda web site: Financial results:
http://www.takeda.com/investor-information/results/ Mid-Range Growth
Strategy: http://www.takeda.com/news/2013/20130509_5767.html

* The exchange rate assumptions for fiscal 2013 are 1US$=90 yen and 1 euro=120

** Special factors affecting operating income: amortization of intangible
assets and goodwill resulting from corporate acquisitions, and an increase in
COGS related to inventory step-up due to revaluation to fair value also
resulting from corporate acquisitions.

*** Special factors affecting net income, EPS: (In addition to the factors
affecting operating income) non-operating expenses related to corporate
acquisitions, refund relating to transfer pricing

**** EBITDA excl. extraordinary income and loss is calculated by adding the
following to ordinary income: amortization of intangible assets, amortization
of goodwill, and non-operating expenses resulting from corporate acquisitions
etc., depreciation and interest expenses.

Forward-looking statements:

This presentation contains forward-looking statements regarding the Company's
plans, outlook, strategies, and results for the future.

All forward-looking statements are based on judgments derived from the
information available to the Company at this time. Forward looking statements
can sometimes be identified by the use of forward-looking words such as "may,"
"believe," "will," "expect," "project," "estimate," "should," "anticipate,"
"plan," "continue," "seek," "pro forma," "potential," "target, " "forecast,"
or "intend" or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to
differ materially from any forward looking statements contained in this
presentation. These risks and uncertainties include, but are not limited to,
(1) the economic circumstances surrounding the Company's business, including
general economic conditions in the US and worldwide; (2) competitive
pressures; (3) applicable laws and regulations; (4) the success or failure of
product development programs; (5) decisions of regulatory authorities and the
timing thereof; (6) changes in exchange rates; (7) claims or concerns
regarding the safety or efficacy of marketed products or product candidates;
and (8) integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or
other information contained in this presentation, whether as a result of new
information, future events, or otherwise.

Contact: Corporate Communications Department, +81-3-3278-2037
Press spacebar to pause and continue. Press esc to stop.